3/19
07:30 am
crvo
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
Low
Report
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
3/18
01:19 pm
crvo
CervoMed (CRVO) had its price target lowered by Roth Mkm from $19.00 to $11.00. They now have a "buy" rating on the stock.
Low
Report
CervoMed (CRVO) had its price target lowered by Roth Mkm from $19.00 to $11.00. They now have a "buy" rating on the stock.
3/18
08:40 am
crvo
CervoMed (CRVO) had its price target raised by Chardan Capital from $15.00 to $21.00. They now have a "buy" rating on the stock.
High
Report
CervoMed (CRVO) had its price target raised by Chardan Capital from $15.00 to $21.00. They now have a "buy" rating on the stock.
3/17
07:30 am
crvo
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
Medium
Report
CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
3/16
03:21 pm
crvo
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
Low
Report
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
3/12
07:00 am
crvo
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
Low
Report
CervoMed Announces Presentations at Upcoming AD/PD™ 2026 Scientific Conference
3/5
08:28 am
crvo
CervoMed (CRVO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
Low
Report
CervoMed (CRVO) had its "buy" rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
3/5
07:30 am
crvo
CervoMed to Participate in Upcoming Investor Conferences
Low
Report
CervoMed to Participate in Upcoming Investor Conferences
3/4
02:49 pm
crvo
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
Low
Report
CervoMed (CRVO) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $31.00 price target on the stock.
3/4
07:30 am
crvo
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Medium
Report
CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
2/18
08:13 am
crvo
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
Medium
Report
CervoMed (NASDAQ:CRVO) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $31.00 price target on the stock.
2/18
06:00 am
crvo
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
Medium
Report
CervoMed’s neflamapimod elected for inclusion in UK EXPERTS-ALS platform designed to prioritize promising treatments for Amyotrophic Lateral Sclerosis
2/6
05:33 pm
crvo
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
Medium
Report
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Cap M to a "strong-buy" rating.
2/5
06:09 am
crvo
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.
Medium
Report
CervoMed (NASDAQ:CRVO) was upgraded by analysts at Brookline Capital Management to a "strong-buy" rating.